A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG

By utilizing a *Drosophila* eye model to screen FDA/EMA-approved compounds, researchers identified that modulating dopamine signaling and cyclooxygenase pathways can rescue the small eye phenotype and alleviate neurological symptoms in PIGA-CDG, offering promising repurposed therapeutic candidates for this currently untreatable disorder.

The Gist

The Big Picture: A Rare Glitch in the Body's "Sticky Tape"

Imagine your body is a massive, bustling construction site. Every cell is a worker, and they need to stick to specific spots or attach tools to their backs to do their jobs. To do this, they use a special kind of "sticky tape" called a GPI anchor.

The PIGA gene is the foreman that makes the glue for this tape. In a rare condition called PIGA-CDG, the foreman is sick (due to a genetic mutation). The glue isn't made properly, so the workers (proteins) can't stick to the walls or hold their tools. This causes chaos, especially in the brain, leading to seizures, developmental delays, and other serious issues.

Currently, doctors can only treat the symptoms (like giving medicine for seizures), but there is no cure because the root cause is so complex and the number of patients is too small to justify the billions of dollars needed to invent a brand-new drug from scratch.

The Strategy: "Repurposing" Instead of "Inventing"

Instead of trying to build a new drug from the ground up (which is like trying to build a car from raw metal), the researchers decided to look at the used car lot. They asked: "Are there already approved, safe drugs out there that might accidentally fix this specific problem?"

They used a fruit fly (Drosophila) as their test subject. Why flies?

• They are cheap and fast.
• They share about 75% of their "instruction manual" (genes) with humans.
• They have a complex eye that acts like a tiny window into the brain.

The Experiment:
The researchers created a line of flies with the "sick foreman" (PIGA mutation). These flies had tiny, glassy eyes—a visible sign that the "glue" wasn't working. They then fed these flies 1,520 different existing drugs (like aspirin, antipsychotics, and allergy meds) to see which ones made the eyes grow back to a normal size.

The Discovery: Two Surprising Fixers

Out of the 1,500+ drugs, they found several that worked. Two main categories stood out:

1. The "Firefighters" (Cyclooxygenase/COX Inhibitors)

• The Analogy: When the "glue" fails, the cells get stressed and start a small fire (inflammation). This inflammation damages the tissue further.
• The Fix: The researchers found that NSAIDs (common painkillers like Naproxen/Aleve) acted as firefighters. They put out the inflammation fire, allowing the eye tissue to recover and grow larger.
• The Result: Flies treated with these drugs had bigger, healthier eyes. This suggests that anti-inflammatory drugs might help PIGA-CDG patients.

2. The "Volume Control" (Dopamine Signaling)

• The Analogy: Imagine the brain is a radio station. The "PIGA glitch" has turned the volume down too low on a specific channel (dopamine), which controls movement and mood. The signal is too weak, causing the "static" (seizures) and "poor reception" (developmental delays).
• The Fix: The researchers found two ways to turn the volume back up:
  • Turn down the "Mute" button: They used drugs that block the Dopamine 2 Receptor (D2R). Think of D2R as a "Mute" button that tells the brain to stop listening to dopamine. By blocking the mute button, the brain hears the dopamine signal louder and clearer.
  • Turn up the "Microphone": They gave the flies L-DOPA (a precursor to dopamine, used for Parkinson's) or blocked the "recycling bin" (DAT) that usually sucks dopamine away. This kept more dopamine floating around in the brain.
• The Result: When they turned up the dopamine volume, the flies' eyes grew bigger. Even better, when they tested these flies on seizures and climbing ability (neurological tests), the flies performed much better. They climbed higher and recovered from seizures faster.

Why This Matters

This study is a huge win for rare disease research for three reasons:

1. Speed: Because they used drugs that are already approved by the FDA, these treatments could potentially move to human patients very quickly. We don't have to wait 10 years for safety trials.
2. New Understanding: They discovered that PIGA-CDG isn't just about "bad glue." It's also about inflammation and dopamine levels. This gives doctors new targets to aim at.
3. Hope for Patients: PIGA-CDG patients suffer from severe, drug-resistant seizures. The fact that tweaking dopamine levels helped flies recover from seizures suggests that existing Parkinson's or psychiatric drugs might be able to help these patients live better lives.

The Bottom Line

The researchers took a "shotgun approach" with a library of old drugs and found that turning up the brain's dopamine volume and calming the inflammation can fix the symptoms of a rare genetic disease in flies. This opens the door to testing these existing, safe drugs on human patients, offering a beacon of hope for a condition that currently has no cure.

Technical Summary

1. Problem Statement

PIGA-CDG (Phosphatidylinositol glycan biosynthesis class A Congenital Disorder of Glycosylation) is an ultra-rare, X-linked recessive neurodevelopmental disorder caused by partial loss-of-function variants in the PIGA gene.

• Pathophysiology: The PIGA gene encodes the catalytic subunit of the GPI-N-acetylglucosaminyl transferase complex, essential for the first step of Glycosylphosphatidylinositol (GPI) anchor biosynthesis. Loss of GPI anchors leads to the depletion of over 150 GPI-anchored proteins (GPI-APs), which are critical for cell signaling, adhesion, and immunity.
• Clinical Challenge: Patients suffer from severe neurological symptoms, including intractable seizures, intellectual disability, developmental delay, and hypotonia. There is currently no disease-specific treatment; management is purely symptomatic.
• Therapeutic Hurdle: Developing de novo drugs for such a small patient population (<100 identified cases) is economically unfeasible due to high costs and lengthy clinical trial timelines.

2. Methodology

The authors employed a drug repurposing strategy using a Drosophila melanogaster (fruit fly) model to rapidly identify FDA/EMA-approved compounds that could ameliorate PIGA-CDG phenotypes.

• Model System:
  • Eye Model: Tissue-specific knockdown of PIGA using the eya-GAL4 driver. This results in a "small eye" phenotype (reduced eye size with a glassy appearance), which serves as a quantitative, high-throughput readout. Ubiquitous knockdown is lethal, necessitating tissue-specific models.
  • Neurological Models:
    • Pan-neuronal knockdown (elav-GAL4): Recapitulates locomotor deficits and erect wing phenotypes.
    • Heterozygous null model: Recapitulates severe seizure susceptibility (bang sensitivity).
• Primary Screen:
  • Library: Prestwick Chemical Library (1,520 compounds; 98% FDA/EMA-approved).
  • Protocol: Flies were reared on food supplemented with 5 µM of each drug.
  • Readout: Eye size was quantified in adult flies. Z-scores were calculated relative to DMSO controls. Compounds with Z ≥ 1.5 were classified as "suppressors" (improving phenotype), and Z ≤ -1.5 as "enhancers."
• Validation:
  • Pharmacological: Secondary validation of hit compounds at various doses (1–50 µM).
  • Genetic: Crosses with mutant alleles or RNAi lines targeting the specific molecular targets of the drug hits (e.g., dopamine receptors, cyclooxygenase enzymes) to confirm mechanism of action.
  • Behavioral Assays: Negative geotaxis (climbing) and Bang Sensitivity (seizure recovery) assays were used to test therapeutic efficacy on neurological phenotypes.

3. Key Contributions & Results

A. Identification of Novel Therapeutic Pathways

From the 1,520 compounds screened, 89 suppressors (improving eye size) and 56 enhancers were identified. The authors prioritized recurrent drug classes, focusing on:

1. Cyclooxygenase (COX) Inhibitors: Six COX inhibitors (e.g., Naproxen, Fenclofenac) suppressed the eye phenotype.
   • Validation: Pharmacological treatment with Naproxen increased eye size by 9–15% depending on dose.
   • Genetic Confirmation: RNAi knockdown of Pxt (the fly ortholog of human COX-1/COX-2) partially rescued the eye size (7.2% increase), confirming that inhibiting prostaglandin synthesis is beneficial.
2. Dopamine Signaling Modulators: Six dopamine-targeting drugs were identified, primarily D2 receptor (Dop2R) antagonists.
   • Validation: Tricyclic D2R antagonists (Quetiapine, Octoclothepin, Mesoridazine) partially rescued eye size (6–13% increase).
   • Genetic Confirmation: Hemizygous loss of Dop2R significantly increased eye size by 18.3%. Conversely, heterozygous loss of Dop1R1 (which stimulates cAMP) worsened the phenotype, suggesting a balance where D2R inhibition is protective.

B. Modulation of Dopamine Availability

The study investigated whether increasing dopamine levels could rescue the phenotype.

• L-DOPA Supplementation: Treating flies with L-DOPA (a dopamine precursor) increased eye size by 19.6% at 25 µM.
• Synthesis Inhibition: Heterozygous loss of ple (tyrosine hydroxylase, the rate-limiting enzyme) worsened the eye phenotype, confirming sensitivity to dopamine levels.
• Reuptake Inhibition: Heterozygous loss of DAT (Dopamine Transporter), which prevents dopamine reuptake, increased eye size by 16.3%.

C. Rescue of Neurological Phenotypes

The authors tested if these genetic manipulations translated to behavioral improvements in more severe models.

• Locomotor Deficits: In the pan-neuronal PIGA knockdown model, loss of Dop2R improved climbing ability (from ~10% to ~25% of flies recovering).
• Seizure Recovery: In the PIGA heterozygous null model (bang sensitivity assay):
  • Loss of Dop2R dramatically improved seizure recovery. In females, recovery at 30 seconds improved from 15% to 52.9%. In males, it improved from 22.4% to 55%.
  • Loss of DAT showed even more dramatic rescue in females (20.3% to 91.7%) and males (31.7% to 83.1%).
• Pharmacological Note: While genetic inhibition of Dop2R rescued seizures, acute pharmacological treatment with D2R antagonists did not, suggesting that developmental rewiring or sustained inhibition is required for neurological rescue.

D. Mechanistic Insights

• COX Pathway: The authors propose that GPI-anchor loss causes ER stress and misfolded protein accumulation, triggering inflammatory signaling. COX inhibition likely mitigates this downstream inflammation.
• Dopamine Pathway: The data suggests that PIGA deficiency disrupts dopaminergic circuitry. Inhibiting D2R (which normally suppresses cAMP) or increasing dopamine availability restores homeostasis. This aligns with findings in other CDG models (DPAGT1-CDG, NGLY1-deficiency), suggesting a generalizable mechanism where glycosylation defects converge on dopaminergic dysregulation.

4. Significance

• Therapeutic Translation: The study identifies COX inhibitors (many available over-the-counter) and dopamine modulators (including L-DOPA and DAT inhibitors) as immediate candidate therapies for PIGA-CDG.
• Clinical Relevance: The findings are particularly significant for treating intractable seizures, a major cause of morbidity in PIGA-CDG. The observation that L-DOPA has already alleviated dyskinesia in a human patient supports the fly model's predictive validity.
• Broader Impact: The work demonstrates that drug repurposing in Drosophila can rapidly uncover shared pathophysiological mechanisms (like dopaminergic dysregulation) across different Congenital Disorders of Glycosylation (CDGs), offering a blueprint for treating other ultra-rare diseases.
• Mechanistic Discovery: It provides the first evidence linking GPI-anchor biosynthesis defects to specific dopaminergic signaling pathways, opening new avenues for understanding the neurological basis of CDGs.

In conclusion, this paper successfully bridges the gap between a rare genetic disorder and actionable therapeutic strategies by leveraging a high-throughput fly screen, validating that modulating dopamine signaling and reducing neuroinflammation can significantly ameliorate both developmental and neurological deficits in PIGA-CDG.